Pharmaceuticals

The Trump administration rolled out a list of actions in its budget proposal to attack drug prices, but most of the measures dance around the edges of the problem.

Alex Azar spent five years in charge of Eli Lilly & Co.'s U.S. operations. During his tenure, the prices for the company's insulin products more than doubled.

Treatment for hepatitis C has improved dramatically in the last decade — so much so that it drew one doctor out of retirement to help make sure more low-income patients are cured.

Food and Drug Commissioner Scott Gottlieb says he wants to know why drugmakers churn out medicines for some rare diseases but not others.

A ProPublica series has illuminated the many ways the U.S. health care system leaks money. Here are some ideas for plugging the holes.

The Pharmaceutical Research and Manufacturers of America, the brand-name drug industry's main trade group, spent liberally to shift the conversation on prices during the last presidential campaign.

The Republican tax plan could reduce or eliminate federal tax credits that reward companies for developing drugs to treat rare diseases. People who benefit from the medicines have objected.

Drug companies and medical device makers in Puerto Rico are still struggling with power and staffing shortages. One device manufacturer says the future of his industry on the island is uncertain.

For more than three decades, pharmaceutical companies have claimed a 50 percent tax credit for the cost of clinical trials of drugs for rare diseases. The credit is now in jeopardy.

Senators cited ProPublica reporting that found drug companies have been making patients pay for oversize eyedrops and more liquid cancer medications than they need.

When eyedrops dribble down your face, it's not your fault. Drugmakers have long known that their drops of medicine exceed the capacity of the human eye. Why didn't companies make the drops smaller?

This is the first step in a long game to develop clearer prescription drug pricing laws around the country, health policy experts say.